Impact of uPA/PAI-1 and disseminated cytokeratin-positive cells in breast cancer
作者： Bruno Märkl , Martin Kazik , Nadia Harbeck , Elzbieta Jakubowicz , Reinhard Hoffmann
DOI: 10.1186/S12885-019-5857-0
关键词: Cancer research 、 Circulating tumor cell 、 Tumor progression 、 T-stage 、 Bone marrow 、 Medicine 、 Breast cancer 、 Cancer 、 Chemotherapy 、 Surgical oncology
摘要: The protease uPA and its inhibitor PAI-1 play major roles in hemostasis are also involved cancer progression. This is mainly caused by their ability to degrade extracellular matrix-facilitating tumor cell migration. study aimed investigate the impact of uPA/PAI-1 disseminated cytokeratin-positive cells (dCK+) on outcome existence synergistic effects. We retrospectively analyzed a cohort 480 breast cases with known dCK+ status. was tested fresh samples using commercial ELISA test. Bone marrow aspirates were investigated immunocytochemically for CK18. DCK+ identified 23% cases. positivity significantly associated occurrence (P = 0.028). subgroup early-stage without chemotherapy. alone not prognostic. However, we found In node-negative chemotherapy, prognostic enhanced additional dCK-positivity (triple +). triple-positive status independently (HR: 9.3 CI: 1.1–75) next T stage. seem influence metastatic potential cells, which underlines important role
biomedcentral.com
springer.com
sci-hub.se 参考文章(37)
Deli Wang, Yihan Li, Xin Wang, Xuan Liu, Bo Fu, Yunzhi Lin, Lois Larsen, Walter Offen, Overview of multiple testing methodology and recent development in clinical trials. Contemporary Clinical Trials. ,vol. 45, pp. 13- 20 ,(2015) , 10.1016/J.CCT.2015.07.014
K. Mengele, N. Harbeck, U. Reuning, V. Magdolen, M. Schmitt, Tumorassoziierte Prognosefaktoren der Plasminogenaktivator-Familie Bestimmung und klinische Wertigkeit von u-PA, t-PA, PAI-1 und PAI-2 Hamostaseologie. ,vol. 25, pp. 301- 310 ,(2005) , 10.1055/S-0037-1619664
Veronica R. Placencio, Yves A. DeClerck, Plasminogen Activator Inhibitor-1 in Cancer: Rationale and Insight for Future Therapeutic Testing Cancer Research. ,vol. 75, pp. 2969- 2974 ,(2015) , 10.1158/0008-5472.CAN-15-0876
B McMahon, HC Kwaan, Brandon J McMahon, The Role of Plasminogen-Plasmin System in Cancer Cancer Treatment and Research. ,vol. 148, pp. 43- 66 ,(2009) , 10.1007/978-0-387-79962-9_4
Michael Schemper, Terry L. Smith, A note on quantifying follow-up in studies of failure time Controlled Clinical Trials. ,vol. 17, pp. 343- 346 ,(1996) , 10.1016/0197-2456(96)00075-X
Joseph S. Palumbo, Jay L. Degen, Mechanisms linking tumor cell-associated procoagulant function to tumor metastasis Thrombosis Research. ,vol. 120, ,(2007) , 10.1016/S0049-3848(07)70127-5
Eva J Kantelhardt, Martina Vetter, Marcus Schmidt, Corinne Veyret, Doris Augustin, Volker Hanf, Christoph Meisner, Daniela Paepke, Manfred Schmitt, Fred Sweep, Gunter von Minckwitz, Pierre-Marie Martin, Fritz Jaenicke, Christoph Thomssen, Nadia Harbeck, Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: Phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6 × FEC versus 3 × FEC/3 × Docetaxel BMC Cancer. ,vol. 11, pp. 140- 140 ,(2011) , 10.1186/1471-2407-11-140
S. Meng, D. Tripathy, S. Shete, R. Ashfaq, H. Saboorian, B. Haley, E. Frenkel, D. Euhus, M. Leitch, C. Osborne, E. Clifford, S. Perkins, P. Beitsch, A. Khan, L. Morrison, D. Herlyn, L. W. M. M. Terstappen, N. Lane, J. Wang, J. Uhr, uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues. Proceedings of the National Academy of Sciences of the United States of America. ,vol. 103, pp. 17361- 17365 ,(2006) , 10.1073/PNAS.0608113103
Christian Thomas, Christoph Wiesner, Sebastian W. Melchior, Folke Schmidt, Rolf Gillitzer, Joachim W. Thüroff, Jesco Pfitzenmaier, Urokinase-plasminogen-activator receptor expression in disseminated tumour cells in the bone marrow and peripheral blood of patients with clinically localized prostate cancer. BJUI. ,vol. 104, pp. 29- 34 ,(2009) , 10.1111/J.1464-410X.2008.08298.X
Cornelia Liedtke, Marc Thill, , AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2016. Breast Care. ,vol. 11, pp. 204- 214 ,(2013) , 10.1159/000446941